Incyte Corp. (INCY)
INCY trades on Nasdaq in Health Care, Biotechnology: Commercial Physical & Biological Resarch. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/0000879169-26-000010-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | INCY on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000879169 |
| SEC industry code | Services-Commercial Physical & Biological Research |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $5.1B |
| Net income | $1.3B |
| Operating income | $1.5B |
| Net margin | 25.0% |
| Operating margin | 29.5% |
| Revenue growth | +21.2% |
| Cash | $3.1B |
| Total assets | $7.0B |
| P/E (computed) | 19.1× |
| P/S (computed) | 4.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-29 |
| Cash and burn | $3.3B cash; operating cash flow $186.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 203,832,492 (2026-10-22); 196,322,703 a year earlier; 224,109,238 three years earlier. | Cover page 2026-10-22 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Philadelphia, Pennsylvania, United States | PCAOB Form AP 2026-02-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $58.3M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $1.6B | -$784.8M | -$675.3M | $3.3B | No debt tags | $6.0B | 10-Q 2026-10-29 |
| Q2 2026 2026-06-30 | $1.7B | $585.6M | $507.7M | $4.0B | No debt tags | $5.8B | 10-Q 2026-07-28 |
| Q1 2026 2026-03-31 | $1.3B | $303.3M | $369.4M | $3.5B | No debt tags | $5.4B | 10-Q 2026-04-28 |
| Q4 2025 2025-12-31 | $1.5B | $299.3M | $543.3M | $3.1B | No debt tags | $5.1B | 10-K 2026-02-10 |
| Q3 2025 2025-09-30 | $1.4B | $424.2M | $559.4M | $2.5B | No debt tags | $4.8B | 10-Q 2026-10-29 |
| Q2 2025 2025-06-30 | $1.2B | $405.0M | $44.7M | $2.0B | No debt tags | $4.6B | 10-Q 2026-07-28 |
| Q1 2025 2025-03-31 | $1.1B | $158.2M | $266.1M | $1.9B | No debt tags | $4.4B | 10-Q 2026-04-28 |
| Q4 2024 2024-12-31 | $1.2B | $201.2M | $381.2M | $1.7B | No debt tags | $4.2B | 10-K 2026-02-10 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2025-02-10 |
| Latest annual report | 10-K | 2026-02-10 |
| Latest quarterly / interim | 10-Q | 2026-10-29 |
| Latest current report | 8-K | 2026-11-13 |
| Latest proxy | DEFA14A | 2026-05-27 |
Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +1.1% |
| 1 month | +11.4% |
| 3 months | +0.4% |
| Year to date | +22.5% |
| 1 year | +14.8% |
| From 52-week high | -6.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Commercial Physical & Biological Resarch
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MEDP | Medpace Holdings Inc. | $648.20 | -0.88% | $18.1B |
| CRL | Charles River Laboratories International Inc. | $335.52 | -0.72% | $16.1B |
| ICLR | ICON plc | $191.40 | -1.67% | $14.7B |
| IQV | IQVIA Holdings Inc. | $264.73 | -0.15% | $43.6B |
| ABSI | Absci Corporation | $7.47 | -11.54% | $1.3B |
| OABI | OmniAb Inc. | $4.89 | -0.41% | $713.3M |
| NRC | NRC Health | $26.33 | -0.87% | $558.8M |
| MXCT | MaxCyte Inc. | $1.18 | -0.84% | $121.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier